文献速递头颈部肿瘤放疗

鼻咽癌Va区预防照射剂量降低的区域控制研究

The regional-control of prophylactic irradiation dose reduction of level Va in nasopharyngeal carcinoma (NPC).
PubMed 文献 · Radiat Oncol · 2026-02-14

本研究回顾性分析2020至2025年51例鼻咽癌患者共102侧颈部的区域控制数据,所有患者接受调强放疗(IMRT)±化疗,Va区作为低危区接受降低的预防剂量。5年总生存率87.8%、无进展生存率79.8%、局部无复发生存率97.8%、无远处转移生存率85.5%,CTV3内无局部失败。结论提示N0、N1和N3期伴或不伴单/双侧VII区孤立转移的鼻咽癌患者,Va区预防照射剂量可降低甚至省略。

要点

  • 51例鼻咽癌102侧颈部接受IMRT,Va区作为低危区降低预防剂量。
  • 5年OS 87.8%、PFS 79.8%、LRFS 97.8%、DMFS 85.5%。
  • CTV3内无局部失败,支持Va区剂量降低或省略。

核心结论

  • N0期、N1和N3期伴或不伴单/双侧VII区孤立转移的鼻咽癌患者,Va区预防照射剂量可降低甚至省略。

研究设计与样本

  • 回顾性分析2020至2025年51例鼻咽癌患者共102侧颈部的区域控制数据,所有患者接受IMRT±化疗。
  • CTV2定义为无淋巴结播散或VII区孤立转移侧的中危淋巴结区(同侧II和III区),CTV3定义为低危淋巴结区仅包括单侧或双侧Va区并单独勾画。
  • 所有患者接受IMRT 30–33次,采用Kaplan-Meier法计算生存率,EQD2按公式EQD2 = d*n((α/β + d)/(α/β + 2d))计算。

主要发现

  • N0、N1、N3期患者分别为8例(15.7%)、40例(78.4%)、3例(5.9%)。
  • 5年OS、PFS、LRFS、DMFS分别为87.8%、79.8%、97.8%、85.5%。
  • 63侧CTV3的Va区接受预防照射剂量降低(12例双侧颈部,39例单侧颈部)。
  • 5个PTV3接受25–34 Gy(EQD2)预防照射剂量,7个PTV3接受48 Gy(EQD2),51个PTV3接受50–51.04 Gy(EQD2),无患者出现CTV3内局部失败。

关键数值与推荐

  • CTV2包括无淋巴结播散或VII区孤立转移侧的同侧II和III区。
  • CTV3仅包括单侧或双侧Va区,每侧单独勾画。
  • PTV3预防照射剂量分别为25–34 Gy(EQD2)(5个)、48 Gy(EQD2)(7个)、50–51.04 Gy(EQD2)(51个)。

临床怎么用

  • 对N0期、N1和N3期伴或不伴单/双侧VII区孤立转移的鼻咽癌患者,可考虑降低Va区预防照射剂量甚至省略。
  • Va区勾画为CTV3时需每侧颈部单独 delineation,并给予降低的预防剂量。

局限性

  • 回顾性研究,样本量51例,来自单中心2020至2025年数据。
  • Va区预防剂量降低的具体剂量分组样本量较小(5个和7个PTV3)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The regional-control of prophylactic irradiation dose reduction of level Va in NPC has not been reported in detailed. We separately evaluated the metastatic nodes of the two sides of each patient’s neck and aim to assess the regional-control based on the irradiation dose reduction of level Va. METHODS AND MATERIALS: We evaluated the regional-control data of 51 NPC patients with 102 neck sides (NS) in our institution from 2020 to 2025. All patients received intensity-modulated radiation therapy (IMRT) ± chemotherapy. The clinical target volume (CTV2) was defined as intermediate risk nodal regions including the ipsilateral level II and III in the NS without nodal spread or with isolated metastases in level VII. CTV3 was defined as low-risk nodal region only including the unilateral or bilateral level Va, and each NS of CTV3 was individually delineated. All patients received IMRT in 30–33 fractions. The Kaplan-Meier method was used to calculate the survival rate, including overall survival (OS), progression-free survival (PFS), local recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS). The equivalent dose in 2 Gy per fraction (EQD2) was calculated according to the formula: EQD2 = d*n((α/β + d)/(α/β + 2d)). RESULTS: The number of patients with N0, N1, and N3 stage is 8 (15.7%), 40 (78.4%), and 3 (5.9%), respectively, the 5- year OS, PFS, LRFS, and DMFS were 87.8%, 79.8%, 97.8%, and 85.5%, respectively. There are 63 CTV3 received prophylactic irradiation dose reduction in level Va (12 patients in the bilateral NS, 39 patients in the unilateral NS). There are 5 PTV3 received prophylactic irradiation dose of 25–34 Gy (EQD2), 7 PTV3 received 48 Gy (EQD2), and 51 PTV3 received 50–51.04 Gy (EQD2), and no patient presented local failure in CTV3. CONCLUSIONS: The prophylactic irradiation dose of level Va can be reduced or even omitted in NPC patients with N0 stage, N1 and N3 stage with or without isolated metastases in the unilateral/bilateral level VII.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Jiang C, Xu C, Zhou D, et al. The regional-control of prophylactic irradiation dose reduction of level Va in nasopharyngeal carcinoma (NPC). Radiat Oncol. 2026. PMID: 41691283. doi:10.1186/s13014-026-02801-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。